News
30m
InvestorsHub on MSNSarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular DystrophyShares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...
Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results